We begin with a computational analysis of your antibody sequence, identifying potential liabilities such as aggregation-prone regions, deamidation sites, and immunogenic T-cell epitopes.

Using advanced molecular modeling and structural analysis, we map the complementarity-determining regions (CDRs) and framework regions to guide precise modifications that enhance function without compromising antigen binding.

We engineer a variety of formats, including scFv, Fab, minibodies.

We specialize in the design and production of bispecific antibodies (BsAbs) using validated platforms like knob-into-hole technology combined with correct light-chain pairing strategies.

Enhanced Effector Function, Silenced Effector Function, Extended Half-life.

We employ proprietary platforms combining CDR grafting and framework optimization to efficiently convert antibodies into humanized variants with minimal immunogenicity and retained high affinity.

We employ high-throughput screening methods (e.g., FACS, SPR/BLI) to rapidly identify lead candidates based on multiple criteria: affinity, expression titer, and thermal stability. This data-driven approach ensures we advance only the most promising candidates, saving time and resources.

FedEx, DHL, and UPS for international priority shipping.

We formulate your antibody in a buffer optimized for long-term stability (-80°C) and immediate use in common applications.

You receive a comprehensive data package, including the CoA, QC graphs, and recommended storage/usage protocols.